Previous close | 285.28 |
Open | 283.79 |
Bid | 265.80 x 1200 |
Ask | 292.75 x 3000 |
Day's range | 277.36 - 285.27 |
52-week range | 261.59 - 473.50 |
Volume | |
Avg. volume | 210,424 |
Market cap | 7.907B |
Beta (5Y monthly) | 0.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Bio-Rad Laboratories...